Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pepper patch takes on pills for chemo nerve pain

NCT ID NCT05840562

Symptom relief Sponsor: Institut Cancerologie de l'Ouest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial compares a capsaicin patch (applied once) to the daily pill duloxetine for treating painful nerve damage caused by chemotherapy. About 274 people whose nerve pain persists at least a month after chemo will be randomly assigned to one treatment. The goal is to see if the patch can reduce pain by 30% or more after six weeks, offering a potential alternative to daily medication.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
capsaicin patch (Qutenza) and duloxetine (Cymbalta)
What this could lead to
If it works, this could offer a new, non-pill option to ease nerve pain from chemotherapy, potentially with fewer side effects than daily oral medication.
What could go wrong
This is an open-label study, so both patients and doctors know which treatment is given, which can bias results. Also, capsaicin patches can cause burning or skin irritation, and the trial is still recruiting, so results are not yet available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 274 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with CIPN manifested by painful symptoms such as numbness and / or tingling and / or burning pain in fingers / hands and toes / feet with a typical distribution in "gloves and socks" beginning after neurotoxic chemotherapy * Painful CIPN as expressed by the BPI-SF (average pain) as ≥ 4/10 * CIPN persisting at least 1 month after completion of chemotherapy with taxanes and/or platinum salts and sensory CIPN grade ≥ 2 according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE v.5.0) grading scale * Stable doses in the 4 weeks before screening, of concomitant neuropathic pain medication (antiepileptic drugs) * Healthy and non-irritated skin on the areas to be treated * Absence of neurotoxic chemotherapy planned during the next 6 months after inclusion * Patient affiliated to a social security scheme * \> 18 years old * Signed written informed consent form Exclusion Criteria: * Presence of known carcinomatous meningitis * Pre-existing known peripheral neuropathy of another aetiology (alcohol, diabetes, …) * Hypersensitivity to Capsaicin or contra-indications to duloxetine (e.g imatinib, tamoxifen) * Patient already treated for this neuropathy with Capsaicin patches * Patient treated by antidepressant drugs at time of inclusion * Uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 90 mmHg) or recent history (\<3 months) of cardiovascular events (stroke, heart attack, pulmonary embolism) * Patients with known severe renal or hepatic failure * Breastfeeding or pregnant women * Persons deprived of liberty or guardianship (including curatorship) * Patient unable to undergo regular medical follow-up for geographical, social or psychological.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chemotherapy-induced peripheral neuropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chemotherapy-induced neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chemotherapy-induced peripheral neuropathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • "L'Hôpital Privé du Confluent "

    RECRUITING

    Nantes, 44200, France

  • CHU Bordeaux

    RECRUITING

    Bordeaux, 33075, France

  • CHU Grenoble

    RECRUITING

    Grenoble, 38043, France

  • Centre Antoine Lacassagne

    RECRUITING

    Nice, 06189, France

  • Centre François Baclesse

    RECRUITING

    Caen, 14076, France

  • Centre Léon Bérard

    RECRUITING

    Lyon, 69373, France

  • Institut Claudius Regaud -IUCT-O

    RECRUITING

    Toulouse, 31059, France

  • Institut de Cancérologie Strasbourg Europe

    RECRUITING

    Strasbourg, 67033, France

  • Institut de Cancérologie de l'Ouest

    RECRUITING

    Angers, 49055, France

  • Institut de Cancérologie de l'Ouest

    RECRUITING

    Saint-Herblain, 44805, France

  • Polyclinique Chenieux

    RECRUITING

    Limoges, 87039, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.